Sunshine Biopharma, Inc. (NASDAQ:SBFMW – Get Free Report) saw a significant growth in short interest during the month of July. As of July 15th, there was short interest totaling 5,818 shares, a growth of 652.7% from the June 30th total of 773 shares. Based on an average trading volume of 5,883 shares, the short-interest ratio is presently 1.0 days.
Sunshine Biopharma Stock Performance
Shares of SBFMW opened at $0.06 on Monday. The company has a 50 day moving average of $0.06 and a two-hundred day moving average of $0.11. Sunshine Biopharma has a twelve month low of $0.02 and a twelve month high of $0.65.
Sunshine Biopharma Company Profile
Sunshine Biopharma is a development-stage biopharmaceutical company focused on the discovery and development of novel small-molecule therapeutics for oncology and antiviral applications. The company’s research activities encompass the design, synthesis and preclinical evaluation of compounds that inhibit key pathways involved in cell proliferation and viral replication.
Among its lead programs, Sunshine Biopharma is advancing Adva-27a, a topoisomerase II inhibitor licensed from the National Research Council of Canada, which is undergoing preclinical studies for potential use in breast and ovarian cancers.
See Also
- Five stocks we like better than Sunshine Biopharma
- RTX and Lockheed Earnings: Can Strong Guidance Reset the Defense Trade?
- These 4 Earnings Reports Expose the Market’s Growing Economic Divide
- Broadcom May Be the Biggest Winner From Alphabet’s Earnings
- Volatility Is Back and These 3 Market Tollbooths Are Best Positioned to Profit
Receive News & Ratings for Sunshine Biopharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Sunshine Biopharma and related companies with MarketBeat.com's FREE daily email newsletter.
